PDS Biotech Regains Nasdaq Compliance, Resolving Delisting Threat
PDSB has more than doubled off its 52-week low of $0.507.
Summary
PDS Biotechnology announced it has regained compliance with Nasdaq's minimum bid price requirement, eliminating the risk of delisting.
Key Events · Corporate Governance and Compliance · PDSB
-
Regains Nasdaq Compliance
The company received notice from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement, closing the previously disclosed deficiency matter.
-
Removes Delisting Threat
This action removes the immediate threat of delisting from The Nasdaq Capital Market, which had been in effect since February 25, 2026.
Analysis · PDSB · Life Sciences
PDS Biotechnology has successfully resolved the Nasdaq minimum bid price deficiency, which had been a concern since February 2026. This removes the immediate risk of delisting, a critical factor for maintaining investor confidence and market liquidity, especially for a company of this size. The company's stock price is now above the $1.00 threshold.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.6M. The 52-week trading range was $0.51 to $1.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.